Director John W. Childs ups Veradermics (MANE) holdings via IPO conversions, buy
Rhea-AI Filing Summary
Veradermics, Inc. director John W. Childs reported multiple equity transactions tied to the company’s initial public offering. On February 5, 2026, entities associated with him converted Series A, B and C convertible preferred stock into Veradermics common shares on a 10.067-for-1 basis, resulting in 480,269, 906,862 and 520,758 common shares, respectively, all held indirectly through J.W. Childs Associates (FL), L.P. The same day, that entity also made an indirect open-market purchase of 294,117 common shares at $17 per share, bringing total indirect common stock holdings to 2,202,006 shares. Separately, on February 3, 2026, Childs received a direct stock option grant for 51,525 shares at a $17 exercise price, which becomes fully vested and exercisable on February 3, 2027.
Positive
- None.
Negative
- None.
Insights
IPO-driven preferred conversions and a modest insider purchase look routine and not thesis-changing.
The disclosure shows preferred shares tied to Veradermics converting automatically into common stock on a 10.067-for-1 basis immediately before the initial public offering. These are structural capitalization changes typical of an IPO, not new cash inflows to the company.
Indirect holdings through J.W. Childs Associates (FL), L.P. rose via both conversion and a 294,117-share open-market buy at $17, taking indirect common ownership to 2,202,006 shares. A 51,525-share stock option grant, vesting on February 3, 2027, adds standard director equity incentives without indicating a shift in business outlook.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series A Convertible Preferred Stock | 480,269 | $0.00 | -- |
| Conversion | Series B Convertible Preferred Stock | 906,862 | $0.00 | -- |
| Conversion | Series C Convertible Preferred Stock | 520,758 | $0.00 | -- |
| Conversion | Common Stock | 480,269 | $0.00 | -- |
| Conversion | Common Stock | 906,862 | $0.00 | -- |
| Conversion | Common Stock | 520,758 | $0.00 | -- |
| Purchase | Common Stock | 294,117 | $17.00 | $5.00M |
| Grant/Award | Stock Option (Right to Buy) | 51,525 | $0.00 | -- |
Footnotes (1)
- On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. Shares held by J.W. Childs Associates (FL), L.P. John W. Childs 2013 Revocable Trust is the sole owner of J.W. Childs Associates (FL), L.P. The Reporting Person, a member of the board of directors of the Issuer, is Trustee of John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities. On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date.
